[REVISION HISTORY]

Quantum BioPharma Lucid-MS development

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-09-23 19:02 UTC → 2026-09-25 18:26 UTC · added ~~removed~~

Quantum BioPharma is developing Lucid-MS, an investigational drug candidate designed to treat multiple sclerosis (MS) by directly inhibiting demyelination. The treatment targets the enzyme peptidyl arginine deiminase 2 (PAD2) to address nerve damage, rather than focusing on immune system suppression like many current therapies. ~~The~~ Following the completion of Phase 1 trials, which indicated a favorable safety profile, the company has received ~~FDA~~ Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to ~~begin phase two~~ proceed with Phase 2 clinical ~~trials for the drug, which~~ testing. This phase aims to evaluate the drug’s ability to protect and repair the myelin sheath. While medical experts view this as a significant shift toward myelin-repair therapy, ~~they note that~~ its ability to reverse existing disability remains uncertain. The development comes amid a global MS patient population of approximately 2.9 million, with nearly one million people living with the condition in the United States. Current approved therapies often fail to reverse the neurodegeneration that leads to long-term disability, highlighting the potential need for approaches like Lucid-MS.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.